guest ::
| Home > Publications database > A framework for assessing interactions for risk stratification models: the example of ovarian cancer. > print |
| Home > Publications database > A framework for assessing interactions for risk stratification models: the example of ovarian cancer. > print |
| 001 | 277473 | ||
| 005 | 20240229155018.0 | ||
| 024 | 7 | _ | |a 10.1093/jnci/djad137 |2 doi |
| 024 | 7 | _ | |a pmid:37436712 |2 pmid |
| 024 | 7 | _ | |a 0027-8874 |2 ISSN |
| 024 | 7 | _ | |a 0198-0157 |2 ISSN |
| 024 | 7 | _ | |a 1460-2105 |2 ISSN |
| 024 | 7 | _ | |a altmetric:151929446 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-01394 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Phung, Minh Tung |b 0 |
| 245 | _ | _ | |a A framework for assessing interactions for risk stratification models: the example of ovarian cancer. |
| 260 | _ | _ | |a Oxford |c 2023 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1699972563_1526 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Nov 8;115(11):1420-1426 |
| 520 | _ | _ | |a Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential interactions between these exposures. We have developed a four-criterion framework for assessing interactions which includes statistical, qualitative, biological, and practical approaches. Using ovarian cancer, we present the application of the framework as this is an important step in developing more accurate risk stratification models. Using data from nine case-control studies in the Ovarian Cancer Association Consortium, we conducted a comprehensive analysis of interactions between 15 unequivocal risk/protective factors for ovarian cancer (including 14 non-genetic factors and a 36-variant polygenic score) with age and menopausal status. Pairwise interactions between the risk/protective factors were also assessed. We found that menopausal status modifies the association between endometriosis, first degree family history of ovarian cancer, breastfeeding, and depot-medroxyprogesterone acetate use and disease risk, highlighting the importance of understanding multiplicative interactions when developing risk prediction models. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Lee, Alice W |b 1 |
| 700 | 1 | _ | |a McLean, Karen |b 2 |
| 700 | 1 | _ | |a Anton-Culver, Hoda |b 3 |
| 700 | 1 | _ | |a Bandera, Elisa V |b 4 |
| 700 | 1 | _ | |a Carney, Michael E |b 5 |
| 700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 6 |u dkfz |
| 700 | 1 | _ | |a Cramer, Daniel W |b 7 |
| 700 | 1 | _ | |a Doherty, Jennifer Anne |b 8 |
| 700 | 1 | _ | |a Turzanski-Fortner, Renée |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 9 |u dkfz |
| 700 | 1 | _ | |a Goodman, Marc T |b 10 |
| 700 | 1 | _ | |a Harris, Holly R |b 11 |
| 700 | 1 | _ | |a Jensen, Allan |b 12 |
| 700 | 1 | _ | |a Modugno, Francesmary |b 13 |
| 700 | 1 | _ | |a Moysich, Kirsten B |b 14 |
| 700 | 1 | _ | |a Pharoah, Paul D P |b 15 |
| 700 | 1 | _ | |a Qin, Bo |b 16 |
| 700 | 1 | _ | |a Terry, Kathryn L |b 17 |
| 700 | 1 | _ | |a Titus, Linda J |b 18 |
| 700 | 1 | _ | |a Webb, Penelope M |b 19 |
| 700 | 1 | _ | |a Group, Australian Ovarian Cancer Study |b 20 |e Collaboration Author |
| 700 | 1 | _ | |a Wu, Anna H |b 21 |
| 700 | 1 | _ | |a Zeinomar, Nur |b 22 |
| 700 | 1 | _ | |a Ziogas, Argyrios |b 23 |
| 700 | 1 | _ | |a Berchuck, Andrew |b 24 |
| 700 | 1 | _ | |a Cho, Kathleen R |b 25 |
| 700 | 1 | _ | |a Hanley, Gillian E |b 26 |
| 700 | 1 | _ | |a Meza, Rafael |b 27 |
| 700 | 1 | _ | |a Mukherjee, Bhramar |b 28 |
| 700 | 1 | _ | |a Pike, Malcolm C |b 29 |
| 700 | 1 | _ | |a Pearce, Celeste Leigh |b 30 |
| 700 | 1 | _ | |a Trabert, Britton |b 31 |
| 700 | 1 | _ | |a Consortium, Ovarian Cancer Association |b 32 |e Collaboration Author |
| 773 | _ | _ | |a 10.1093/jnci/djad137 |g p. djad137 |0 PERI:(DE-600)1465951-7 |n 11 |p 1420-1426 |t Journal of the National Cancer Institute |v 115 |y 2023 |x 0027-8874 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:277473 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-18 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JNCI-J NATL CANCER I : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b JNCI-J NATL CANCER I : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|